Smart Cancer Guide

In the evolving healthcare landscape of 2026, cancer is no longer viewed solely through a genetic lens. It is recognized as a complex, adaptive ecosystem that is simultaneously genetic, metabolic, immunological, and ecological. While standard treatments remain the core foundation, the integration of metabolic oncology has become essential for addressing the "downstream manifestations" of genetic mutations. The Metabolic Debate: Warburg vs. OXPHOS The metabolic theory of cancer, popularized by Professor Tom Seyfried , focuses on Otto Warburg’s discovery that cancer cells prefer aerobic glycolysis (fermentation) due to mitochondrial dysfunction. Seyfried’s "Press-Pulse" strategy seeks to "starve" these cells by restricting glucose and glutamine while pulsing with metabolic inhibitors. However, 2026 expert Jane McLelland highlights a critical "blind spot": not all cancers are glycolytic . Many common tumors, such as ER+ breast...

Executive Summary Over the past several years, repurposed antiparasitic drugs—particularly fenbendazole , mebendazole , and ivermectin —have attracted widespread attention in oncology communities. A publicly accessible compilation hosted by OneDayMD documents more than 700 anecdotal cancer cases reporting tumor regression, stabilization, or remission while using these agents, often in combination with conventional therapy or adjunctive supplements. This report does not treat these anecdotes as proof of efficacy. Instead, it applies pharmacovigilance logic, bias analysis, mechanistic plausibility review, and comparative survival context to assess whether this body of reports constitutes: Noise Wishful thinking Or a legitimate hypothesis-generating signal Conclusion: The dataset does not constitute mainstream clinical evidence. However, the signal density, mechanistic plausibility, and cross-cancer recurrence pattern justify formal prospective evaluation under controlled conditions. 1. ...

Pancreatic ductal adenocarcinoma (PDAC) remains one of the deadliest human malignancies, with a five-year survival rate stubbornly below 15% despite decades of advances in surgery, chemotherapy, and molecular oncology. Most discussions focus on late diagnosis, aggressive genetics, or therapeutic resistance. Far less attention is paid to a quieter but increasingly evident factor: insulin resistance and metabolic dysfunction . Emerging evidence suggests that pancreatic cancer is not merely influenced by metabolic disease—it may be deeply intertwined with it . Insulin resistance often precedes diagnosis, worsens prognosis, and biologically fuels tumor growth. Yet it remains largely absent from staging systems, risk stratification, and treatment frameworks. A 2023 study from researchers at University of British Columbia’s Faculty of Medicine reveals a direct link between high insulin levels, common among patients with obesity and type 2 diabetes, and pancreatic cancer. The study, published...

The global oncology market has entered a dynamic new phase in 2026—defined by immunotherapy dominance, rapid CAR-T expansion, and next-generation targeted delivery mechanisms. While legacy pharmaceutical giants still command massive baseline revenues, financial and clinical data from the first half of 2026 reveal a clear shift: long-term survival in this sector requires aggressive platform M&A activity, companion diagnostics, and defense strategies against upcoming patent cliffs. This comprehensively updated 2026 analysis breaks down the leading oncology drug companies, evaluating them by revenue performance, core pipeline assets, and their strategic resilience against market pressures. 2026 Landscape: Top Oncology Revenue Drivers at a Glance Company Flagship Oncology Asset Primary 2026 Strategic Focus Looming Headwind Merck & Co. (MRK) Keytruda (pembrolizumab) Co-formula...

Cancer treatment has changed dramatically over the past few decades. For much of modern medical history, chemotherapy was the primary systemic therapy used to treat cancer. Today, immunotherapy is transforming the field of oncology by enabling the immune system to recognize and attack cancer cells. Patients newly diagnosed with cancer often face a confusing array of treatment options. Many ask important questions such as: Is immunotherapy better than chemotherapy? What are the risks and benefits of each treatment? Which cancers respond best to immunotherapy? Can these therapies be combined? What happens if immunotherapy fails? Understanding the differences between chemotherapy and immunotherapy can help patients make more informed decisions together with their healthcare providers. This comprehensive guide explains how these treatments work, their effectiveness, side effects, survival outcomes, costs, and emerging innovations in cancer therapy. Credit:  Statista What Is Chemother...

Pancreatic cancer has long been one of the most feared diagnoses in oncology—aggressive, late-detected, and historically resistant to treatment. But 2026 marks a potential turning point. Revolution Medicines announced results Monday from a Phase 3 trial showing taking daraxonrasib by mouth daily nearly doubled survival, with patients living 13.2 months compared to 6.7 months on standard intravenous chemotherapy. Patients were eligible for the trial if they had metastatic pancreatic cancer and had already progressed on another treatment. Revolution Medicines CEO Mark Goldsmith called the results "unprecedented," noting no drug has ever demonstrated a survival benefit of more than a year in a Phase 3 pancreatic cancer trial. Update (May 2026): Daraxonrasib Pancreatic Cancer Drug : New RAS Inhibitor Doubles Survival in Phase 3 Trial What Is Daraxonrasib, and How Does It Work? Daraxonrasib is an investigational oral medication developed by Revolution Medicines, a clinical-s...

Written by: Steve Fong Medically Reviewed by: One Day MD Editorial Team Cancer treatment is no longer a one-size-fits-all approach. Advances in precision medicine now allow doctors to better understand the unique biology of each patient's cancer and make more informed treatment decisions. One important innovation in this field is the Prosigna® Test . What Is the Prosigna Test? The Prosigna Test is a genomic assay designed for certain types of early-stage breast cancer. By analyzing the expression of 50 genes within a tumor (known as the PAM50 gene signature), the test helps estimate the risk of cancer recurrence and provides valuable information about the tumor's molecular subtype. Unlike traditional pathology tests that focus primarily on how cancer cells appear under a microscope, the Prosigna Test examines the tumor's underlying genetic activity, offering a deeper understanding of its biological behavior. Why Is the Prosigna Test Important? Traditionally, breast cancer t...